Fred Hutch Hosts Inaugural Dr E. Donnall Thomas Symposium
October 27th 2022Leading researchers from around the globe visited Fred Hutchinson Cancer Center to honor Dr E. Donnall Thomas and to discuss the future of transplantation, gene, and cellular therapies at the inaugural Dr E. Donnall Thomas Symposium.
ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC
Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.
Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC
September 12th 2022The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.
Brachytherapy Represents a Potential Strategy in AYA Patients With Rhabdomyosarcoma
February 9th 2022Although brachytherapy is rarely utilized as a treatment for pediatric and adolescent/young adult patients in the United States, AYA patients with rhabdomyosarcoma treated with BT had favorable survival outcomes.
Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL
January 12th 2022Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL
December 22nd 2021Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Parsaclisib Elicits Encouraging Response Rates in Relapsed/Refractory Follicular Lymphoma
Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study.
Maintenance Therapy, Adjuvant and Escalated Approaches Garner Excitement in GU Cancers
October 11th 2021Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.